Emily Collins Kulze, PA-C in Washington, DC - Medicare

Emily Collins Kulze, PA-C is a medicare enrolled "Physician Assistant" physician in Washington, District Of Columbia. Her current practice location is 5215 Loughboro Rd Nw Ste 200, Washington, District Of Columbia. You can reach out to her office (for appointments etc.) via phone at (301) 657-1996.

Emily Collins Kulze is licensed to practice in South Carolina (license number 2854) and she also participates in the medicare program. She accepts medicare assignments (which means she accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and her NPI Number is 1073021697.

Contact Information

	Emily Collins Kulze, PA-C
	5215 Loughboro Rd Nw Ste 200, Washington, DC 20016-2625
	(301) 657-1996
	Not Available

Physician's Profile

Full Name	Emily Collins Kulze
Gender	Female
Speciality
Experience	Years
Location	5215 Loughboro Rd Nw Ste 200, Washington, District Of Columbia
Accepts Medicare Assignments	Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.

Medical Education and Training:

Emily Collins Kulze attended and graduated from in

NPI Data:

NPI Number: 1073021697
Provider Enumeration Date: 01/17/2018
Last Update Date: 08/04/2022

Medicare PECOS Information:

PECOS PAC ID:
Enrollment ID:

Medical Identifiers

Medical identifiers for Emily Collins Kulze such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1073021697	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207P00000X	Emergency Medicine	2854 (South Carolina)	Secondary
207X00000X	Orthopaedic Surgery	2854 (South Carolina)	Secondary
363A00000X	Physician Assistant	2854 (South Carolina)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Emily Collins Kulze is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Emily Collins Kulze, PA-C 5215 Loughboro Rd Nw Ste 200, Washington, DC 20016-2625 Ph: (301) 657-1996	Emily Collins Kulze, PA-C 5215 Loughboro Rd Nw Ste 200, Washington, DC 20016-2625 Ph: (301) 657-1996

News Archive

Apitope's ATX-F8-117 granted FDA Orphan Drug Designation for treatment of haemophilia A patients

Apitope, the drug discovery and development company focused on disease-modifying treatments that reinstate immune tolerance, announced today that pre-clinical product candidate ATX-F8-117 has been granted Orphan Drug Status by the US Food and Drug Administration for the prevention or treatment of inhibitors in haemophilia A patients with inhibitors or at the risk of producing inhibitors.

Abused women more likely to seek emergency contraception, study finds

Women who experience domestic violence and abuse are more than twice as likely to seek emergency contraception as other women, according to a study by National Institute for Health Research-funded researchers at the University of Bristol and Queen Mary University of London, suggesting that requests for emergency contraception could be an important sign of abuse.

Environment plays a key role in determining sexual over asexual reproduction

Evolutionary biologists at the University of Toronto (U of T) have found that environment plays a key role in determining whether a species opts for sexual over asexual reproduction.

Study sheds new light on the body's initial response to DENV infection

A study led by scientists at the Walter Reed Army Institute of Research sheds new light on the body's initial response to dengue virus (DENV) infection, describing the molecular diversity and specificity of the antibody response.

Comprehensive analysis of the human and mouse transcriptomes

An international consortium of scientists, including a team from The University of Queensland's Institute for Molecular Bioscience (IMB), is a step closer to the next generation of treatments to combat disease, after publishing a comprehensive analysis of the human and mouse transcriptomes.

Emily Collins Kulze, PA-C - Medicare in Washington, DC